{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T22:38:04Z","timestamp":1765233484033,"version":"3.37.3"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T00:00:00Z","timestamp":1677110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T00:00:00Z","timestamp":1677110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s12328-023-01775-0","type":"journal-article","created":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T14:04:47Z","timestamp":1677161087000},"page":"422-431","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Three cases of immune-related hypopituitarism after atezolizumab\u2013bevacizumab treatment for hepatocellular carcinoma"],"prefix":"10.1007","volume":"16","author":[{"given":"Nozomi","family":"Furuichi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Naganuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Kaburagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhei","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Hoshino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyuki","family":"Shibusawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suguru","family":"Horiguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Hatanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0224-7093","authenticated-orcid":false,"given":"Satoru","family":"Kakizaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshio","family":"Uraoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,2,23]]},"reference":[{"key":"1775_CR1","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.jhep.2017.09.016","volume":"68","author":"N Fujiwara","year":"2018","unstructured":"Fujiwara N, Friedman SL, Goossens N, et al. Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine. J Hepatol. 2018;68:526\u201349.","journal-title":"J Hepatol"},{"key":"1775_CR2","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","volume":"391","author":"A Forner","year":"2018","unstructured":"Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391:1301\u201314.","journal-title":"Lancet"},{"key":"1775_CR3","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","volume":"69","author":"European Association for the Study of the Liver","year":"2018","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182\u2013236.","journal-title":"J Hepatol"},{"key":"1775_CR4","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1159\/000368142","volume":"87","author":"M Kudo","year":"2014","unstructured":"Kudo M, Matsui O, Izumi N, et al. Transarterial chemoembolization failure\/refractoriness: JSH-LCSGJ criteria 2014 update. Oncology. 2014;87:22\u201331.","journal-title":"Oncology"},{"key":"1775_CR5","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus Bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894\u2013905.","journal-title":"N Engl J Med"},{"key":"1775_CR6","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1159\/000514174","volume":"10","author":"M Kudo","year":"2021","unstructured":"Kudo M, Kawamura Y, Hasegawa K, et al. Management of hepatocellular carcinoma in Japan: JSH consensus statements and recommendations 2021 Update. Liver Cancer. 2021;10:181\u2013223.","journal-title":"Liver Cancer"},{"key":"1775_CR7","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","volume":"33","author":"MA Postow","year":"2015","unstructured":"Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015;33:1974\u201382.","journal-title":"J Clin Oncol"},{"key":"1775_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.953761","volume":"13","author":"SL Ou","year":"2022","unstructured":"Ou SL, Luo J, Wei H, et al. Safety and efficacy of programmed cell death 1 and programmed death ligand-1 inhibitors in the treatment of cancer: an overview of systematic reviews. Front Immunol. 2022;13: 953761.","journal-title":"Front Immunol"},{"key":"1775_CR9","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.2217\/fon.15.52","volume":"11","author":"JR Brahmer","year":"2015","unstructured":"Brahmer JR, Hammers H, Lipson EJ. Nivolumab: targeting PD-1 to bolster antitumor immunity. Future Oncol. 2015;11:1307\u201326.","journal-title":"Future Oncol"},{"key":"1775_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.886930","volume":"13","author":"CA Muir","year":"2022","unstructured":"Muir CA, Tsang VHM, et al. Immune related adverse events of the thyroid - a narrative review. Front Endocrinol (Lausanne). 2022;13: 886930.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1775_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2022.101668","volume":"36","author":"T Mizukoshi","year":"2022","unstructured":"Mizukoshi T, Fukuoka H, Takahashi Y. Immune checkpoint inhibitor-related hypophysitis. Best Pract Res Clin Endocrinol Metab. 2022;36: 101668.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"1775_CR12","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41574-021-00484-3","volume":"17","author":"JJ Wright","year":"2021","unstructured":"Wright JJ, Powers AC, Johnson DB. Endocrine toxicities of immune checkpoint inhibitors. Nat Rev Endocrinol. 2021;17:389\u201399.","journal-title":"Nat Rev Endocrinol"},{"key":"1775_CR13","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3389\/fonc.2020.00091","volume":"10","author":"AR Almutairi","year":"2020","unstructured":"Almutairi AR, McBride A, Slack M, et al. Potential immune-related adverse events associated with monotherapy and combination therapy of ipilimumab, nivolumab, and pembrolizumab for advanced melanoma: a systematic review and meta-analysis. Front Oncol. 2020;10:91.","journal-title":"Front Oncol"},{"key":"1775_CR14","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1186\/s13046-020-01749-x","volume":"39","author":"XH Jia","year":"2020","unstructured":"Jia XH, Geng LY, Jiang PP, et al. The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors. J Exp Clin Cancer Res. 2020;39:284.","journal-title":"J Exp Clin Cancer Res"},{"key":"1775_CR15","unstructured":"Pharmaceuticals and Medical Devices Agency. Risk Management Plan for ipilimumab plus nivolumab. 2022. https:\/\/www.pmda.go.jp\/RMP\/www\/180188\/a3a75261-9c19-4494-a9ff-cb2cf22dfa5b\/180188_4291427A1024_10_014RMPm.pdf Accessed 5th Dec 2022"},{"key":"1775_CR16","unstructured":"Pharmaceuticals and medical devices agency. Risk management plan for nivolumab. 2022. https:\/\/www.pmda.go.jp\/RMP\/www\/180188\/a3a75261-9c19-4494-a9ff-cb2cf22dfa5b\/180188_4291427A1024_09_015RMPm.pdf Accessed 5th Dec 2022"},{"key":"1775_CR17","unstructured":"Pharmaceuticals and medical devices agency. Risk management plan for pembrolizumab. https:\/\/www.pmda.go.jp\/RMP\/www\/170050\/bb2e759c-bd7f-4577-b27c-342a2524de1d\/170050_4291435A1029_01_013RMPm.pdf Accessed 5th Dec 2022"},{"key":"1775_CR18","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1016\/j.ajpath.2016.08.020","volume":"186","author":"P Caturegli","year":"2016","unstructured":"Caturegli P, Di Dalmazi G, Lombardi M, et al. Hypophysitis Secondary to cytotoxic T-lymphocyte-associated protein 4 blockade: insights into pathogenesis from an autopsy series. Am J Pathol. 2016;186:3225\u201335.","journal-title":"Am J Pathol"},{"key":"1775_CR19","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1586\/17512433.2016.1133289","volume":"9","author":"E Rossi","year":"2016","unstructured":"Rossi E, Sgambato A, De Chiara G, et al. Endocrinopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancer. Expert Rev Clin Pharmacol. 2016;9:419\u201328.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"1775_CR20","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1126\/scitranslmed.3008002","volume":"6","author":"S Iwama","year":"2014","unstructured":"Iwama S, De Remigis A, Callahan MK, et al. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med. 2014;6:230\u201345.","journal-title":"Sci Transl Med"},{"key":"1775_CR21","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s11102-015-0671-4","volume":"19","author":"A Faje","year":"2016","unstructured":"Faje A. Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights. Pituitary. 2016;19:82\u201392.","journal-title":"Pituitary"},{"key":"1775_CR22","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ejca.2019.03.002","volume":"113","author":"E Guerrero","year":"2019","unstructured":"Guerrero E, Johnson DB, Bachelot A, et al. Immune checkpoint inhibitor-associated hypophysitis-world health organisation vigibase report analysis. Eur J Cancer. 2019;113:10\u20133.","journal-title":"Eur J Cancer"},{"key":"1775_CR23","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1158\/1078-0432.CCR-14-2353","volume":"21","author":"L Min","year":"2015","unstructured":"Min L, Hodi FS, Giobbie-Hurder A, et al. Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study. Clin Cancer Res. 2015;21:749\u201355.","journal-title":"Clin Cancer Res"},{"key":"1775_CR24","doi-asserted-by":"publisher","first-page":"19419","DOI":"10.1038\/s41598-019-56026-5","volume":"9","author":"J Garon-Czmil","year":"2019","unstructured":"Garon-Czmil J, Petitpain N, Rouby F, et al. Immune check point inhibitors-induced hypophysitis: a retrospective analysis of the French Pharmacovigilance database. Sci Rep. 2019;9:19419.","journal-title":"Sci Rep"},{"key":"1775_CR25","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature21349","volume":"541","author":"DS Chen","year":"2017","unstructured":"Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541:321\u201330.","journal-title":"Nature"},{"key":"1775_CR26","first-page":"4229","volume":"37","author":"R Ariyasu","year":"2017","unstructured":"Ariyasu R, Horiike A, Yoshizawa T, et al. Adrenal insufficiency related to anti-programmed death-1 therapy. Anticancer Res. 2017;37:4229\u201332.","journal-title":"Anticancer Res"},{"key":"1775_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000779","volume":"8","author":"T Kobayashi","year":"2020","unstructured":"Kobayashi T, Iwama S, Yasuda Y, et al. Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study. J Immunother Cancer. 2020;8: e000779.","journal-title":"J Immunother Cancer"},{"key":"1775_CR28","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1210\/jc.2012-4075","volume":"98","author":"SM Corsello","year":"2013","unstructured":"Corsello SM, Barnabei A, Marchetti P, et al. Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab. 2013;98:1361\u201375.","journal-title":"J Clin Endocrinol Metab"},{"key":"1775_CR29","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1097\/01.cji.0000178913.41256.06","volume":"28","author":"JA Blansfield","year":"2005","unstructured":"Blansfield JA, Beck KE, Tran K, et al. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother. 2005;28:593\u20138.","journal-title":"J Immunother"},{"key":"1775_CR30","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1053\/j.seminoncol.2010.09.003","volume":"37","author":"KC Kaehler","year":"2010","unstructured":"Kaehler KC, Piel S, Livingstone E, et al. Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management. Semin Oncol. 2010;37:485\u201398.","journal-title":"Semin Oncol"},{"key":"1775_CR31","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s11102-009-0193-z","volume":"13","author":"T Dillard","year":"2010","unstructured":"Dillard T, Yedinak CG, Alumkal J, et al. Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes. Pituitary. 2010;13:29\u201338.","journal-title":"Pituitary"}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-023-01775-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12328-023-01775-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-023-01775-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T13:12:57Z","timestamp":1684588377000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12328-023-01775-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,23]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["1775"],"URL":"https:\/\/doi.org\/10.1007\/s12328-023-01775-0","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"type":"print","value":"1865-7257"},{"type":"electronic","value":"1865-7265"}],"subject":[],"published":{"date-parts":[[2023,2,23]]},"assertion":[{"value":"13 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest in association with the present study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures followed have been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}},{"value":"The written informed consent was obtained from patients for this case report.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}